Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis

Proceedings of the American Thoracic Society

Volumn 4, Issue 4, 2007, Pages 359-363

  Ramsey, Bonnie W ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Cystic fibrosis; Lung imaging

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; DORNASE ALFA; MUCOLYTIC AGENT; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANALYTICAL PARAMETERS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CYSTIC FIBROSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EPIDEMIOLOGICAL DATA; GENE THERAPY; HEALTH CARE QUALITY; HUMAN; INTERVENTION STUDY; MORTALITY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; SCORING SYSTEM; VALIDATION STUDY;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CYSTIC FIBROSIS; HUMANS; INFANT; LUNG; OUTCOME ASSESSMENT (HEALTH CARE); PRODUCT SURVEILLANCE, POSTMARKETING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34548246514     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200611-183HT     Document Type: Conference Paper

References (36)

1. NIH Definitions Working Group. Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model. In: Downing GJ, editor. Biomarkers and surrogate endpoints: clinical research and applications. Amsterdam: Elsevier; 2000. pp. 1-9.
2. Smith JJ, Sorensen AG, Thrall JH. Biomarkers in imaging: realizing radiology's future. Radiology 2003;227:633-638.
3. Aziz ZA, Davies JC, Alton EW, Wells AU, Geddes DM, Hansell DM. Computed tomography and cystic fibrosis: promises and problems. Thorax 2007;62:181-186.
4. New drug, antibiotic and biological drug product regulations; accelerated approval: proposed rule. Fed Regist 1992;57:13234-13242.
5. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, editors. Clinical measurement in drug evaluation. New York: Wiley; 1995. pp. 3-22.
6. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
7. Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med 2006;174:780-786.
8. Kang EY, Miller RR, Muller NL. Bronchiectasis: comparison of preoperative thin-section CT and pathologic findings in resected specimens. Radiology 1995;195:649-654.
9. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004;144:154-161.
10. de Jong PA, Nakano Y, Hop WC, Long FR, Coxson HO, Pare PD, Tiddens HA. Changes in airway dimensions on computed tomography scans of children with cystic fibrosis. Am J Respir Crit Care Med 2005;172:218-224.
11. de Jong PA, Lindblad A, Rubin L, Hop WC, de Jongste JC, Brink M, Tiddens HA. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax 2006;61:80-85.
12. de Jong PA, Nakano Y, Lequin MH, Mayo JR, Woods R, Pare PD, Tiddens HA. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004;23:93-97.
13. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004;145:32-38.
14. Helbich TH, Heinz-Peer G, Fleischmann D, Wojnarowski C, Wunderbaldinger P, Huber S, Eichler I, Herold CJ. Evolution of CT findings in patients with cystic fibrosis. AJR Am J Roentgenol 1999;173:81-88.
15. Brody AS, Sucharew H, Campbell JD, Millard SP, Molina PL, Klein JS, Quan J. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med 2005;172:1128-1132.
16. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, Moss RB. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest 2005;128:2327-2335.
17. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized tomography and chest X-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001;31:377-382.
18. Food and Drug Administration. E8 International Conference on Harmonisation. Guidance on general considerations for clinical trials. Fed Regist 1997;62:66113-66119.
19. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, Gore EJ, Redding GJ. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7:265-271.
20. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, Wu M, Chernick MS, Crystal RG. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992;326:812-815.
21. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase 1 study. JAMA 1992;267:1947-1951.
22. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250.
23. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
24. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
25. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
26. Strugess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 1982;106:303-311.
27. Brody AS, Kosorok MR, Li Z, Broderick LS, Foster JL, Laxova A, Bandla H, Farrell PM. Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. J Thorac Imaging 2006;21:14-21.
28. de Jong PA, Ottink MD, Robben SG, Lequin MH, Hop WC, Hendriks JJ, Pare PD, Tiddens HA. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004;231:434-439.
29. Brody AS, Tiddens HA, Castile RG, Coxson HO, de Jong PA, Goldin J, Huda W, Long FR, McNitt-Gray M, Rock M, et al. Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med 2005;172:1246-1252.
30. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
31. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128:2347-2354.
32. Aurora P, Bush A, Gustafsson P, Oliver C, Wallis C, Price J, Stroobant J, Carr S, Stocks J, London Cystic Fibrosis C. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005;171:249-256.
33. American Thoracic Society. ATS/ERS Statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med 2005;172:1463-1471.
34. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. National Hypertonic Saline in Cystic Fibrosis Study G: a controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240.
35. de Jong PA, Ottink MD, Robben SG, Lequin MH, Hop WC, Hendriks JJ, Pare PD, Tiddens HA. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004;231:434-439.
36. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, Holmes TH, Moss RB. Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;168:588-593.